Prometa

**Prometa** is a branded addiction-treatment regimen rather than a single new molecular entity. Public clinical-trial and publication records describe the PROMETA protocol as a **combination of flumazenil, gabapentin, and hydroxyzine**, used off-label with the goal of reducing withdrawal symptoms, craving, and relapse in substance use disorders, particularly methamphetamine dependence. The program was marketed by **Hythiam** and studied in academic trials, including a placebo-controlled UCLA study in methamphetamine abuse, but published controlled evidence found the protocol was **not superior to placebo** for methamphetamine dependence. Because the queried name refers to the branded multi-drug protocol itself, the best annotation is as a **combination pharmaceutical product/program** rather than a distinct single active ingredient.

Brand names

Prometa

Other names

PROMETAPROMETA protocolPROMETA pharmacotherapyGabasync